The following is an excerpt from a press release from Genentech. Read the press release in its entirety here.
Genentech, a member of the Roche Group, announced that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA® prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors, were published in the Aug. 30, 2018, issue of the New England Journal of Medicine .
“In the HAVEN 3 study, HEMLIBRA showed a significant and clinically meaningful reduction in bleeds in people with hemophilia A without factor VIII inhibitors, while offering multiple subcutaneous dosing options,” said Dr. Johnny Mahlangu, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa. “The publication of these results in the New England Journal of Medicine represents a major advance for hemophilia research and reinforces the potential of HEMLIBRA to change the standard of care for people with hemophilia A.”
Read the press release in its entirety here.